Skip to main content

DESARROLLO DE BIONANOPARTICULAS COMO VACUNAS PARA LA INDUCCION DE INMUNIDAD EN MUCOSAS Y HERRAMIENTAS DE DIAGNOSTICO PARA EL CONTROL Y PREVENCION DE ENFERMEDADES GANADERAS

PID2022-140925OB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Design of Novel Vaccines Based on Virus-Like Particles

  • Bárcena, Juan
  • Zamora-Ceballos, María
  • Blanco Lavilla, Esther
Virus-like particles (VLPs) are formed by viral proteins that, when overexpressed, spontaneously self-assemble into particles that structurally are similar to infectious virus or subviral particles (e.g. the viral capsid). VLPs are appealing as vaccine candidates because their inherent properties (i.e. virus-sized, multimeric antigens, highly organised and repetitive structure, not infectious) are suitable for the induction of safe and efficient humoral and cellular immune responses. VLP-based vaccines have already been licensed for human and veterinary use, and many more vaccine candidates are currently in late stages of evaluation. Moreover, the development of VLPs as platforms for foreign antigen display has further broadened their potential applicability both as prophylactic and therapeutic vaccines. This chapter provides an overview on the design and use of VLPs for the development of new-generation vaccines., Their work is funded by grants from the Spanish Ministry of Science and Innovation (PID2019-107145RB-I00 and PID2022-140925OB-I00); Comunidad de Madrid co-financed with ECFEDER funds (S2018/BAA-4370 PLATESA 2) and European Union’s Horizon 2020 Research and Innovation Programme (VetBioNet, grant agreement No. 731014 and LAGMED, PRIMA S2–11-PCI2019–103732)., Peer reviewed